Inherited retinal diseases can profoundly affect a child’s vision and development, yet there are no approved drug treatments for most of these conditions in children. In this episode of Eye on Innovation, host Carey Powers speaks with Carmen Carrichio, CEO and founder of RareSight, about why pediatric inherited retinal diseases have historically received less attention and investment than adult diseases — and how advances in genetic testing and clinical assessment are beginning to change that.

In this episode, learn about: 

  • Why treatments developed for adults cannot simply be applied to children
  • Where gene therapy may fit into the future of care
  • RareSight’s approach to developing treatments designed to remain in the eye longer
  • How these treatments will change the trajectory of a child’s life

 

RESOURCES: 

Carey Powers: Carey Powers, MBA | Ophthalmology Innovation Source  

Rss
Podden och tillhörande omslagsbild på den här sidan tillhör OIS Podcast. Innehållet i podden är skapat av OIS Podcast och inte av, eller tillsammans med, Poddtoppen.